| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Research and development | 14,969 | 20,276 | 13,531 | |
| General and administrative | 4,101 | 4,457 | 4,433 | |
| Total operating expenses | 19,070 | 24,733 | 17,964 | |
| Loss from operations | -19,070 | -24,733 | -17,964 | |
| Other income, net | 1,047 | 1,224 | 1,409 | |
| Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds | - | - | -10,060 | |
| Change in fair value of warrant liabilities | -564 | -12,293 | - | |
| Net income (loss) | -17,459 | -11,216 | -6,495 | |
| Earnings per share, basic, total | -0.21 | -0.13 | -0.08 | |
| Earnings per share, diluted, total | -0.21 | -0.13 | -0.08 | |
| Weighted average number of shares outstanding, basic, total | 77,156,068 | 77,156,068 | 77,126,763 | |
| Weighted average number of shares outstanding, diluted, total | 77,156,068 | 77,156,068 | 77,126,763 | |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)